Survival after acute myocardial infarction has improved significantly in the past
years and decades. Besides the developments in interventional treatment options, the
increasing public awareness of typical symptoms has contributed to a reduced time
lag between the onset of symptoms and intervention. However, the differential diagnosis
of acute or chronic myocardial ischemia in patients who present with atypical symptoms
can be much less straightforward.
1
Despite current guidelines that allow for 1-hour ruling in or out of non–ST-elevation
myocardial infarction for certain high-sensitivity troponin assays, patients are often
left anxious and stressed during the waiting period for the second troponin measurement.
For other disorders like coronary microvascular disease, diagnostic plasma or serum
markers have not yet been identified.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Contemporary emergency department management of patients with chest pain: a concise review and guide for the high-sensitivity troponin era.Can J Cardiol. 2018; 34: 98-108
- Circulating MIF levels predict clinical outcomes in patients with ST-elevation myocardial infarction after percutaneous coronary intervention.Can J Cardiol. 2019; 35: 1366-1376
- Macrophage migration inhibitory factor (MIF): a glucocorticoid counter-regulator within the immune system.Crit Rev Immunol. 2017; 37: 359-370
- Mechanism of a reaction in vitro associated with delayed-type hypersensitivity.Science. 1966; 153: 80-82
- Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction.Proc Natl Acad Sci U S A. 1966; 56: 72-77
- Macrophage migration inhibitory factor.Crit Care Med. 2002; 30: S27-S35
- MIF regulates innate immune responses through modulation of Toll-like receptor 4.Nature. 2001; 414: 920-924
- Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis.Circulation. 2002; 105: 1561-1566
- Macrophage migration inhibitory factor in cardiovascular disease.Circulation. 2008; 117: 1594-1602
- Role of IL-37 in cardiovascular disease inflammation.Can J Cardiol. 2019; 35: 923-930
- Hematological parameters outperform plasma markers in predicting long-term mortality after coronary angiography.Angiology. 2018; 69: 600-608
- Macrophage migration inhibitory factor for the early prediction of infarct size.J Am Heart Assoc. 2013; 2e000226
- Higher neutrophil/lymphocyte ratio is related to lower ejection fraction and higher long-term all-cause mortality in ST-elevation myocardial infarction patients.Can J Cardiol. 2014; 30: 1177-1182
- Association of lymphocyte-to-monocyte ratio with in-hospital and long-term major adverse cardiac and cerebrovascular events in patients with ST-elevated myocardial infarction.Medicine (Baltimore). 2017; 96: e7897
- A single preoperative blood test predicts postoperative sepsis and pneumonia after coronary bypass or open aneurysm surgery.Eur J Clin Invest. 2019; 49e13055
- Commonly available hematological biomarkers are associated with the extent of coronary calcifications.Atherosclerosis. 2018; 275: 166-173
Article info
Publication history
Published online: June 08, 2019
Accepted:
June 1,
2019
Received:
May 21,
2019
Footnotes
See article by Zhao et al., pages 1366–1376 of this issue.
See page 1282 for disclosure information.
Identification
Copyright
© 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Circulating MIF Levels Predict Clinical Outcomes in Patients With ST-Elevation Myocardial Infarction After Percutaneous Coronary InterventionCanadian Journal of CardiologyVol. 35Issue 10
